Kwak Jinok, Doo Hyunok, Kim Eun Sol, Keum Gi Beom, Ryu Sumin, Choi Yejin, Kang Juyoun, Kim Haram, Chae Yeongjae, Kim Sheena, Lee Ju-Hoon, Kim Hyeun Bum
Department of Animal Biotechnology, Dankook University, Cheonan 31116, Korea.
Division of Infectious Diseases, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
J Anim Sci Technol. 2025 May;67(3):636-650. doi: 10.5187/jast.2024.e93. Epub 2025 May 31.
Canine and human atopic dermatitis (AD) is a complex inflammatory skin disorder with an increasing incidence, characterized by distinct acute and chronic phases with unique histological and immunological profiles. Although research into effective treatment methods has been insufficient, there has been a surge in the exploration of probiotics as a therapeutic strategy for AD. Such probiotics are often originated from the animals, and these are being developed to modulate the immune system and enhance skin barrier function, offering promising new treatment options for AD. To better understand the pathogenesis of both canine and human AD and develop treatments, animal models that accurately replicate the symptoms of both species are indispensable. This study aimed to establish a standardized and cost-effective BALB/c mouse model to more accurately simulate canine and human AD using dinitrochlorobenzene (DNCB) alone and in combination with ovalbumin (OVA). We evaluated histological and immunological changes from acute to chronic stages of AD in the mouse model induced by treatment of DNCB alone and DNCB combined with OVA to determine their similarity to both canine and human AD symptoms. The results showed that the pathological changes observed in the mouse AD model demonstrated significant parallels with both species, including increased mast cell infiltration, epidermal thickening, and elevated cytokine levels such as interleukin-4 and interferon-γ. Acute phase observations highlighted pronounced epidermal defects such as dryness and skin erosion, while chronic phase findings indicated persistent skin thickening, inflammation, and notable edema. Although both mouse models showed comparable symptoms and immunological responses, the model induced by the combination of DNCB and OVA more accurately represented canine and human AD compared to the model induced by DNCB alone. This combined DNCB and OVA mouse model provides valuable insights into AD pathogenesis and potential therapeutic targets, underscoring its significance in AD research.
犬类和人类特应性皮炎(AD)是一种发病率不断上升的复杂炎症性皮肤病,其特征为具有独特组织学和免疫学特征的明显急性期和慢性期。尽管对有效治疗方法的研究尚不充分,但益生菌作为AD治疗策略的探索却激增。这类益生菌通常源自动物,目前正在开发用于调节免疫系统和增强皮肤屏障功能,为AD提供了有前景的新治疗选择。为了更好地理解犬类和人类AD的发病机制并开发治疗方法,准确复制这两个物种症状的动物模型必不可少。本研究旨在建立一种标准化且经济高效的BALB/c小鼠模型,以更准确地模拟犬类和人类AD,单独使用二硝基氯苯(DNCB)以及将其与卵清蛋白(OVA)联合使用。我们评估了在单独使用DNCB以及DNCB与OVA联合处理诱导的小鼠模型中,从AD急性期到慢性期的组织学和免疫学变化,以确定它们与犬类和人类AD症状的相似性。结果表明,在小鼠AD模型中观察到的病理变化与这两个物种都有显著相似之处,包括肥大细胞浸润增加、表皮增厚以及白细胞介素-4和干扰素-γ等细胞因子水平升高。急性期观察结果突出了明显的表皮缺陷,如干燥和皮肤糜烂,而慢性期结果则表明皮肤持续增厚、炎症和明显水肿。尽管两种小鼠模型都表现出可比的症状和免疫反应,但与单独使用DNCB诱导的模型相比,DNCB与OVA联合诱导的模型更准确地代表了犬类和人类AD。这种DNCB与OVA联合的小鼠模型为AD发病机制和潜在治疗靶点提供了有价值的见解,凸显了其在AD研究中的重要性。